Cencora deepens its oncology push with a $2.4 billion American Oncology Network deal
Cencora is moving deeper into community oncology with a signed definitive agreement to acquire American Oncology Network, a physician-led managed services organization valued at $2.4 billion. The transaction would lift Cencora’s ownership from roughly 4% to 75% if eligible current stockholders roll over equity and retain the remaining 25% interest. Board approval is already in place. Stockholder approval and regulatory clearances still stand between the company and closing.
The deal reaches beyond a simple ownership change. It expands Cencora’s role inside the infrastructure that supports independent cancer practices, where purchasing, distribution, administrative support, and clinical coordination are tightly linked to whether smaller groups can keep delivering care outside hospital systems. AON spans 21 states and includes more than 350 oncology providers. Cencora said the acquisition would extend its own oncology managed services presence into 12 additional states.
The strategic logic is clear. Community oncology runs on scale, distribution reliability, care navigation, and operational discipline, and those are exactly the pressure points wholesalers increasingly want to influence. By taking control of AON, Cencora is buying access to a network that can move pharmaceuticals, data, support tools, and practice services through a more integrated channel. In oncology, where treatment regimens are expensive, time-sensitive, and often biologically complex, even small gains in coordination can affect how quickly patients move from diagnosis to therapy.
A network built around independent practices
Fort Myers, Florida-based AON launched in 2018 and serves community oncology practices with both clinical services and administrative support. Its model is built for smaller groups that want to remain independent while outsourcing parts of the operational burden that can overwhelm a private practice. For many practices, that means access to centralized support without surrendering their local identity or patient relationships.
Chief medical officer Stephen “Fred” Divers, M.D., framed the partnership around sustaining high-quality care in patients’ own communities. That emphasis matters in oncology, where travel burdens, infusion schedules, and follow-up demands can quickly turn geography into a clinical barrier. Keeping care local can reduce missed visits, preserve continuity, and make it easier for patients to stay engaged through long treatment courses.
Cencora’s leadership described the acquisition as an expansion of its physician-led oncology managed services organization and part of a broader effort to strengthen patient access to high-quality, cost-effective care. In practical terms, the company is betting that tightly linked distribution and practice support can create a more durable business model than either function could sustain alone.
One sentence captures the economics: Cencora expects the purchase to improve adjusted earnings per share in the second year after closing.
Why the oncology MSO race keeps intensifying
This is not Cencora’s first major move in the space. In late 2025, the company agreed to acquire a majority stake in OneOncology, a separate oncology network in which it had already held a minority position since 2023. The AON transaction widens that footprint and suggests a deliberate segmentation strategy across the community oncology market.
Evercore analysts described AON as more focused on smaller oncology providers, while OneOncology serves larger community practices, with some overlap in capabilities. That distinction gives Cencora coverage across different practice profiles rather than a one-size-fits-all model. The same note pointed to limited integration risk because Cencora has been invested in AON since 2020 and already acts as its distribution partner.
The arrangement also fits a larger consolidation pattern among drug distributors and wholesalers. Cardinal Health has pursued stakes in GI Alliance, Advanced Diabetes Supply Group, Integrated Oncology Network, Specialty Networks, and Solaris Health, while McKesson has closed major deals involving Community Oncology Revitalization Enterprise Ventures and PRISM Vision. The competitive logic is straightforward: control or influence over specialty practices can stabilize distribution, increase service penetration, and create recurring revenue streams in markets that are hard to access through commodity channels alone.
For oncology specifically, managed services organizations can become the connective tissue between clinical autonomy and corporate scale. They may handle revenue cycle functions, technology support, compliance work, and supply chain management, allowing oncologists to focus on treatment decisions while relying on a larger platform for the mechanics of practice survival. The business model only works if the platform can preserve physician trust. Once that trust erodes, referrals, retention, and local market share can deteriorate quickly.
Earnings implications and execution risk still remain
Cencora said it would provide more detail on the transaction during an earnings call scheduled for early November. Analysts at Evercore offered a preliminary earnings view tied to a late-March 2027 close, estimating a $0.02 adjusted earnings per share dilution in fiscal 2027, followed by $0.10 accretion in fiscal 2028 and $0.22 accretion in fiscal 2029. Those projections remain preliminary, but they suggest a path toward earnings contribution after the integration phase passes.
The company also updated its fiscal year 2027 guidance to at least $17.90 in adjusted earnings per diluted share, the upper end of its prior range, citing strength in the U.S. Healthcare Solutions segment. That update places the oncology acquisition inside a wider growth story rather than treating it as a standalone bet.
Still, the transaction depends on regulatory review and stockholder approval, and large healthcare acquisitions rarely close without some operational friction. Independent oncology practices bring different payer contracts, different service mixes, and different regional market dynamics. A network that works well in one state can face reimbursement pressure or referral shifts in another. Even with Cencora’s existing relationship to AON, scaling a physician-led platform across a broader ownership structure will require careful execution.
The transaction also arrives at a time when specialty practice assets have become prized targets across the distribution sector. Those assets are attractive because they sit close to prescribing behavior, infusion delivery, and the operational spine of outpatient specialty care. In oncology, where drug spend is high and clinical demand is rising, control of the support layer can be as strategically valuable as control of the drug shelf itself.
Cencora’s acquisition of AON is therefore more than a financial transaction. It is a bid to shape how community cancer care is organized, financed, and supported across a wider national footprint, with the outcome still contingent on approvals, integration discipline, and whether independent practices see enough value to stay inside the platform.